These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 12477284)

  • 1. Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain.
    Chauhan NB
    Antisense Nucleic Acid Drug Dev; 2002 Oct; 12(5):353-7. PubMed ID: 12477284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular uptake of intracerebroventricularly administered biotin- or digoxigenin-labeled antisense oligodeoxynucleotides in the rat.
    Yee F; Ericson H; Reis DJ; Wahlestedt C
    Cell Mol Neurobiol; 1994 Oct; 14(5):475-86. PubMed ID: 7621508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS.
    Boado RJ; Tsukamoto H; Pardridge WM
    J Pharm Sci; 1998 Nov; 87(11):1308-15. PubMed ID: 9811482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Site-specific administration of antisense oligonucleotides using biodegradable polymer microspheres provides sustained delivery and improved subcellular biodistribution in the neostriatum of the rat brain.
    Khan A; Sommer W; Fuxe K; Akhtar S
    J Drug Target; 2000; 8(5):319-34. PubMed ID: 11328659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution and Penetration of Intracerebroventricularly Administered 2'OMePS Oligonucleotide in the Mouse Brain.
    Casaca-Carreira J; Temel Y; Larrakoetxea I; Jahanshahi A
    Nucleic Acid Ther; 2017 Feb; 27(1):4-10. PubMed ID: 27753537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain.
    Ogawa S; Brown HE; Okano HJ; Pfaff DW
    Regul Pept; 1995 Oct; 59(2):143-9. PubMed ID: 8584749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery across the blood-brain barrier of antisense directed against amyloid beta: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein.
    Banks WA; Farr SA; Butt W; Kumar VB; Franko MW; Morley JE
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1113-21. PubMed ID: 11356936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion.
    Broaddus WC; Prabhu SS; Gillies GT; Neal J; Conrad WS; Chen ZJ; Fillmore H; Young HF
    J Neurosurg; 1998 Apr; 88(4):734-42. PubMed ID: 9525721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrastriatal and intraventricular injections of oligodeoxynucleotides in the rat brain: tissue penetration, intracellular distribution and c-fos antisense effects.
    Grzanna R; Dubin JR; Dent GW; Ji Z; Zhang W; Ho SP; Hartig PR
    Brain Res Mol Brain Res; 1998 Dec; 63(1):35-52. PubMed ID: 9838035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on uptake, sub-cellular trafficking and efflux of antisense oligodeoxynucleotides in glioma cells using self-assembling cationic lipoplexes as delivery systems.
    Islam A; Handley SL; Thompson KS; Akhtar S
    J Drug Target; 2000; 7(5):373-82. PubMed ID: 10721799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
    Wu D; Boado RJ; Pardridge WM
    J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo delivery of phosphorothioate oligonucleotides into murine retina.
    Hangai M; Tanihara H; Honda Y; Kaneda Y
    Arch Ophthalmol; 1998 Mar; 116(3):342-8. PubMed ID: 9514488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral administration of antisense oligonucleotides targeting the amyloid-β protein precursor reverses AβPP and LRP-1 overexpression in the aged SAMP8 mouse brain.
    Erickson MA; Niehoff ML; Farr SA; Morley JE; Dillman LA; Lynch KM; Banks WA
    J Alzheimers Dis; 2012; 28(4):951-60. PubMed ID: 22179572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.
    Geary RS; Norris D; Yu R; Bennett CF
    Adv Drug Deliv Rev; 2015 Jun; 87():46-51. PubMed ID: 25666165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo injection of antisense oligodeoxynucleotides to G alpha subunits and supraspinal analgesia evoked by mu and delta opioid agonists.
    Sánchez-Blázquez P; García-España A; Garzón J
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1590-6. PubMed ID: 8531133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opsonized erythrocyte ghosts for liver-targeted delivery of antisense oligodeoxynucleotides.
    Kim SH; Kim EJ; Hou JH; Kim JM; Choi HG; Shim CK; Oh YK
    Biomaterials; 2009 Feb; 30(5):959-67. PubMed ID: 19027156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense oligonucleotides fail to inhibit the expression of central beta adrenergic receptors.
    Zhang K; O'Donnell JM
    Res Commun Mol Pathol Pharmacol; 1997 Jan; 95(1):21-32. PubMed ID: 9055346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells.
    Ginobbi P; Geiser TA; Ombres D; Citro G
    Anticancer Res; 1997; 17(1A):29-35. PubMed ID: 9066627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligodeoxyribonucleotides: stability and distribution after intracerebral injection into rat brain.
    Szklarczyk A; Kaczmarek L
    J Neurosci Methods; 1995 Aug; 60(1-2):181-7. PubMed ID: 8544478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodistribution of Radioactively Labeled Splice Modulating Antisense Oligonucleotides After Intracerebroventricular and Intrathecal Injection in Mice.
    Metz T; Welling MM; Suidgeest E; Nieuwenhuize E; de Vlaam T; Curtis D; Hailu TT; van der Weerd L; van Roon-Mom WMC
    Nucleic Acid Ther; 2024 Feb; 34(1):26-34. PubMed ID: 38386285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.